Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07736950) titled 'A Randomised Phase 3 Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma' on July 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Australasian Leukaemia and Lymphoma Group

Condition: Follicular Lymphoma

Intervention: Drug: Surovatamig

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: January 12, 2027

Target Sample Size: 138

To know more, visit https:...